FGFR2 and breast carcinoma: GP369, a monoclonal antibody directed against the extracellular ligand-binding structural domain of FGFR2, showed promising results in FGFR2-IIIb subtype of breast cancer cell lines, demonstrating inhibition of tumour proliferation (71).